Rolls-Royce share price targets 1,500p ahead of earnings and buyback - Invezz# Rolls-Royce share price targets 1,500p ahead of earnings and buyback[Europe]Author[Crispus Nyaga]Feb 23, 2026, 09:22 AM- The company will also announce strong financial results.- Sky News reported that the company will announce a new buyback this week.- Rolls-Royce stock price surged to a record high this month.Rolls-Royce share price continued soaring last week and reached a record high as market participants waited for its fina ...

Core Insights - The FDA is planning to phase out petroleum-based synthetic dyes in food, indicating a shift towards safer food additives [1] - The FDA is addressing concerns over the mass compounding of GLP-1 drugs, particularly in relation to telehealth companies like Hims & Hers [4][6] - The FDA's recent decision to review Moderna's mRNA flu shot application reflects ongoing regulatory challenges and industry concerns about consistency [7][9] Group 1: FDA's Regulatory Actions - The FDA is serious about cracking down on unlawful mass compounding of GLP-1s, citing quality and safety concerns [4] - The agency plans to restrict GLP-1 ingredients in non-approved compounded drugs, emphasizing compliance with federal law [4] - FDA Commissioner Makary expressed hope that illegal mass compounding of GLP-1s could end by 2026, contingent on compliance from manufacturers [6] Group 2: Moderna's Flu Shot Application - The FDA has reversed its earlier decision and will review Moderna's application for an experimental mRNA flu shot, with a decision expected by August 5 [7] - Makary stated that the FDA's guidance to Moderna was clear regarding trial design, particularly for older adult participants [8] - Moderna has contested the FDA's requirements for trial comparators, arguing that they are inconsistent with prior communications [9] Group 3: U.S. Drug Development Landscape - Makary warned that the U.S. is falling behind China in early-stage drug development, highlighting the need for reforms to streamline clinical trial processes [10][11] - He identified key bottlenecks in the drug development process, including hospital contracting and ethics reviews, which hinder competitiveness [12] - The FDA is exploring partnerships with health systems and academic centers to expedite the pre-IND process, aiming to enhance domestic innovation [13]

Core Insights - Eli Lilly's Omvoh (mirikizumab-mrkz) demonstrated durable efficacy in maintaining steroid-free remission in over 90% of patients with Crohn's disease for three years, as per the VIVID-2 study results [1][2] - The treatment also showed significantly low rates of hospitalizations and surgeries in patients with both Crohn's disease and ulcerative colitis, indicating its potential to alter disease progression [1][2] - Omvoh is the only IL-23p19 inhibitor to exhibit strong and sustained efficacy over four years in ulcerative colitis and three years in Crohn's disease, with consistent monthly dosing [1][2] Efficacy and Remission - In the VIVID-2 study, 92.4% of patients maintained clinical remission, and 91.2% achieved corticosteroid-free clinical remission after three years of treatment [1][2] - Improvements in bowel urgency were noted, with 82.1% of patients experiencing a 3-point reduction on the Urgency Numeric Rating Scale (UNRS) [1][2] - Sustained improvement in inflammation was observed, with a continued decrease in inflammatory biomarkers over three years [1][2] Safety and Complications - The long-term safety profile of Omvoh remained consistent with known safety data, with common adverse events including upper respiratory tract infections and arthralgia [1][2][3] - Omvoh reduced Crohn's disease-related hospitalizations and surgeries by nearly 50% in the first 12 weeks compared to placebo, and by nearly 70% during weeks 12 to 52 [1][2] - In the LUCENT-3 study for ulcerative colitis, only one hospitalization and no surgeries were reported during the three-year extension [1][2] Regulatory and Clinical Development - Omvoh has received regulatory approvals for treating moderately to severely active ulcerative colitis and Crohn's disease in adults across 47 countries [2] - Ongoing studies are exploring combination therapies with mirikizumab to enhance treatment efficacy while maintaining long-term safety [2] - Pediatric trials for Omvoh in ulcerative colitis and Crohn's disease are also in progress [2]

Core Insights - Eli Lilly and Company (LLY) is a leader in the diabetes and obesity treatment market, driven by the success of its GLP-1 therapies, Mounjaro and Zepbound, which utilize tirzepatide for effective treatment [1][2] Industry Overview - The global obesity drug market is expected to grow significantly, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates [3] - Both Lilly and Novo Nordisk are competing to develop next-generation GLP-1 treatments, including oral options, to maintain their market leadership [3] Product Pipeline - Lilly is investing in obesity treatments with several new molecules in clinical development, including oral and injectable medications [4] - A key candidate in Lilly's obesity pipeline is orforglipron, a once-daily oral GLP-1 small molecule, which could lower treatment burden and broaden patient adoption [5] - Positive data from six studies on orforglipron has led to regulatory applications in the U.S., EU, and other countries, with a U.S. launch expected in Q2 2026 [6][11] - Lilly is also evaluating orforglipron in late-stage studies for other conditions, expanding its revenue potential beyond obesity and type II diabetes [7] - Another candidate, retatrutide, is being studied for obesity and knee osteoarthritis pain, with plans for approval in 2026 [8][9] Competitive Landscape - Competition in the obesity market is intensifying, with Novo Nordisk set to launch an oral version of Wegovy in January 2026, potentially impacting Lilly's market share [12] - Smaller biotech companies are also developing oral GLP-1 drugs, such as Viking Therapeutics and Structure Therapeutics, which may further increase competition [13][14] Financial Performance - Lilly's stock has increased by 19.5% over the past year, compared to the industry's 18.2% rise [15] - The stock is currently trading at a price/earnings ratio of 29.70, higher than the industry average of 18.82, but below its 5-year mean of 34.57 [17] - The Zacks Consensus Estimate for 2026 has risen from $33.15 to $33.80 per share, indicating positive revisions in earnings expectations [20]

Core Viewpoint - Australia's CSL has entered into an exclusive licensing agreement with Eli Lilly and Co, allowing CSL to develop and commercialize clazakizumab, an antibody targeting specific medical conditions [1] Group 1: Licensing Agreement - The agreement grants CSL certain rights related to the development and commercialization of clazakizumab [1] - This partnership is expected to enhance CSL's portfolio in the biopharmaceutical sector [1] Group 2: Product Focus - Clazakizumab is an antibody aimed at treating specific medical conditions, indicating a focus on innovative therapies [1] - The collaboration with Eli Lilly highlights CSL's commitment to expanding its therapeutic offerings [1]

To further harness global opportunity in pharma and life sciences, Indian industry needs to move up on the value chain to become a capability leader with focus on high-value products, according to industry captains. The journey towards this end has just begun and may take a decade or more to achieve tangible results, said panelists of a discussion on the future of pharma and biotech over the next five years, during the CEO Conclave at the BioAsia 2026, here on Tuesday.“India did become the generic pharma hu ...

Core Insights - Eli Lilly aims to establish India as a global export hub for its pharmaceutical products, leveraging a $1 billion investment in contract manufacturing [1] - The company's weight-loss drug Mounjaro has seen sales double shortly after its launch in India, becoming the top-selling medicine by value in the country [1] - Lilly plans to introduce additional products in India, including the Alzheimer's drug donanemab and potential future obesity treatments, pending regulatory approvals [1] Company Strategy - Eli Lilly does not currently have its own manufacturing facility in India but intends to export drugs produced locally to global markets [1] - The company is focused on enhancing digital and social media campaigns to raise awareness about obesity and expand Mounjaro's reach in smaller cities [1] - Partnerships with local firms, such as Cipla and digital health platforms like Tata 1MG, Practo, and Apollo, are part of Lilly's strategy to widen distribution [1] Market Competition - In India, Eli Lilly competes with Novo Nordisk, which produces Wegovy, as the market for weight-loss drugs is expected to grow significantly [1] - Novo Nordisk has reduced the price of Wegovy by up to 37% to maintain market share, but Lilly believes Mounjaro's superior efficacy will keep it competitive [1] - The expiration of Novo's patent on semaglutide is anticipated to lead to the launch of cheaper generic versions of Wegovy by local firms [1]

Core Insights - Eli Lilly's Q4 earnings exceeded expectations with an EPS of $7.54 compared to the expected $6.67, and the company projected 2026 revenue between $80 billion and $83 billion [1] - The company's Mounjaro revenue increased by 110% to $7.4 billion in Q4, while Zepbound revenue rose by 123% to $4.2 billion [1] - Eli Lilly's operating margins reached 45.6% and net margins were at 31.7%, indicating strong financial performance [1] Financial Performance - Eli Lilly's stock was trading at $1,040, just 5.8% below its all-time high as of February 13, 2026 [1] - Retail sentiment shifted from neutral to bullish, with a sentiment score increase from 57.3 to 65.7 following the earnings report [1] - Analysts maintain a consensus target price of $1,201, with some projecting a higher target of $1,350 based on the company's growth potential [1] Strategic Initiatives - Eli Lilly has committed $1 billion to develop a supercomputer in collaboration with Nvidia to enhance drug discovery processes [1] - The establishment of a co-innovation lab with Nvidia aims to integrate clinical data with advanced computational capabilities [1] - The company has built a $1.5 billion stockpile of orforglipron, anticipating an FDA decision in April 2026, positioning itself for market capture [1] Competitive Landscape - Eli Lilly's GLP-1 franchise is outperforming competitors, with significant revenue growth compared to Novo Nordisk, which is facing projected sales declines of 5% to 13% in 2026 [1] - The company's quarterly revenue growth was reported at 42.6%, indicating strong momentum in its product pipeline [1]

Core Insights - Eli Lilly's Retevmo (selpercatinib) shows significant event-free survival benefits as an adjuvant therapy for early-stage RET fusion-positive lung cancer, meeting its primary endpoint in the Phase 3 LIBRETTO-432 trial [1] - The trial demonstrated a statistically significant improvement in event-free survival (EFS) compared to placebo, although overall survival results were still immature at the time of analysis [1] - The study reinforces the importance of genomic testing for patients diagnosed with early-stage lung cancer [1] Group 1: Clinical Trial Results - LIBRETTO-432 is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer (NSCLC) [1] - The trial enrolled 151 patients, randomized 1:1 to receive either selpercatinib or placebo, with the primary endpoint being EFS assessed by investigators [1] - Secondary endpoints included overall survival, EFS assessed by blinded independent central review, and time to distant disease recurrence [1] Group 2: Patient Demographics and Disease Context - NSCLC accounts for approximately 85% of all lung cancer diagnoses in the U.S., with around 30% of patients presenting with stage IB-IIIA disease [1] - About 50% of NSCLC patients have actionable biomarkers, with RET fusions identified in 1-2% of all NSCLC cases [1] Group 3: Safety Profile - The overall safety profile of selpercatinib in LIBRETTO-432 was consistent with previous trials, with serious hepatic adverse reactions occurring in 3% of patients [2] - Increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed in 59% and 55% of patients, respectively [2] - Hypertension occurred in 41% of patients, with Grade 3 hypertension in 20% [2] Group 4: Future Directions - Detailed results from the LIBRETTO-432 trial will be presented at an upcoming medical congress and submitted for peer review [1] - The company aims to accelerate the use of genomic testing for all patients diagnosed with early-stage lung cancer based on these findings [1]

Core Insights - The article discusses the significant potential of artificial intelligence (AI) in drug development, particularly highlighting Eli Lilly's initiatives in this area [1][7]. Company Overview - Eli Lilly is a major player in the pharmaceutical industry with a market capitalization of $983 billion and a current stock price of $1,040.00 [4]. - The company has a gross margin of 83.04% and a dividend yield of 0.74% [5]. AI Initiatives - Eli Lilly launched its TuneLab platform in September, which provides digital access to its proprietary data on drug molecule performance, aiding in drug discovery [5]. - The average cost of bringing a new drug to market is approximately $1 billion, making the efficiency gained through AI significant [6]. - In October, Eli Lilly announced a partnership with Nvidia, committing $1 billion to develop a supercomputer aimed at enhancing drug discovery and understanding of diseases [7]. Market Potential - The AI-powered drug discovery industry is projected to grow at an average annual rate of 30% through 2034, potentially reaching a value of over $20 billion [9]. - Eli Lilly's current annual revenue is around $65 billion, indicating that while the AI drug discovery market is a fraction of its revenue, it represents a significant growth opportunity [10]. Strategic Partnerships - The collaboration with Nvidia has led to the establishment of a co-innovation lab to accelerate medicine discovery and production, linking clinical testing data with advanced computational capabilities [7]. - Eli Lilly's AI platform has already attracted third-party biopharma customers, indicating a growing interest in its technological capabilities [8].